<DOC>
	<DOCNO>NCT01432483</DOCNO>
	<brief_summary>The purpose study provide continue therapy Denileukin diftitox ( ONTAK ) patient currently therapy suitable treatment option , therapy request physician .</brief_summary>
	<brief_title>Access Program With Denileukin Diftitox Treatment Patients Currently Receiving Treatment With Commercially Available ( Ontak )</brief_title>
	<detailed_description>The Access Program provide long appropriate accord judgment provider . If Denileukin diftitox ( ONTAK ) become commercially available without restriction , access program discontinue .</detailed_description>
	<mesh_term>Denileukin diftitox</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>To receive denileukin diftitox ( ONTAK ) protocol , patient 's physician must request therapy specific patient . Patients may continue treatment denileukin diftitox : Are currently therapy denileukin diftitox require ongoing therapy maintain control disease . Are willing able comply aspect Access Protocol Provide write informed consent participate Patients eligible Access Program denileukin diftitox : â€¢ Are currently denileukin diftitox therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Cancer</keyword>
	<keyword>ONTAK</keyword>
	<keyword>Denileukin diftitox</keyword>
	<keyword>persistent recurrent disease</keyword>
	<keyword>require continue delivery essential cancer therapy</keyword>
</DOC>